Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05486871
Collaborator
(none)
30
1
2
24
1.2

Study Details

Study Description

Brief Summary

RCC represents around 3% of all cancers, with the highest incidence occurring in Western countries . Within the several RCC risk factors identified, smoking, obesity, and hypertension are most strongly associated with RCC .

The EUA guidelines recommend PN for patients with T1 tumors, as PN preserved kidney function better after surgery, thereby potentially lowering the risk of development of cardiovascular disorders as well as improving overall survival(OS) for PN compared to RN, there is very limited evidence on the optimal surgical treatment for patients with larger renal masses (T2) .

Currently, the upper limit of PN indications remains undefined and is determined by an individual surgeon's expertise and preference. The degree of variability in the choice between PN and RN for a given tumor increases with tumor size. Surgeons committed to nephron-sparing are likely to expand the indications of PN, while those concerned with increased morbidity and doubtful of the clinical relevance of a moderate decrease in renal function are likely to perform RN, regardless of tumor size .

Condition or Disease Intervention/Treatment Phase
  • Procedure: laparoscopic partial nephrectomy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.
Anticipated Study Start Date :
Aug 20, 2022
Anticipated Primary Completion Date :
Aug 20, 2024
Anticipated Study Completion Date :
Aug 20, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: renal cell carcinoma stages T1

laparoscopic partial nephrectomy in renal cell carcinoma stage T1

Procedure: laparoscopic partial nephrectomy
This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study: Group [A] : 15 patients with T1 RCC (≤ 7 cm). Group [B] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes.

Active Comparator: renal cell carcinoma stages T2a

laparoscopic partial nephrectomy in renal cell carcinoma stage T2a

Procedure: laparoscopic partial nephrectomy
This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study: Group [A] : 15 patients with T1 RCC (≤ 7 cm). Group [B] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes.

Outcome Measures

Primary Outcome Measures

  1. Renal function. [3month]

    Patients' pre and postoperative eGFR values were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation, with the postoperative eGFR based on the creatinine measurement taken closest to 1 yr after surgery (between 9 and 15 month postoperatively). The eGFR downgrade was defined as preoperative eGFR 60 ml/min/1.73 m2 and postoperative eGFR <60 ml/min/1.73 m2 at 1 yr after surgery.

  2. Post-operative complications. [3 month]

    complications within 90 days of operation were prospectively collected and classified based on the modified Clavien -Dindo grading system

  3. Local recurrence. [3 month]

    radiological investigation in the form of contrast enhanced CT abdomen and pelvis or MRI incase of raised serum creatinine

  4. Distant metastases. [3 month]

    radiological investigation in the form of contrast enhanced CT abdomen and pelvis or MRI incase of raised serum creatinine and bone scan incase of bone pain or pathological fractures CT BRAIN incase of manifestation of increased intracranial tension

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with localized RCC ≤ 10 cm in preoperative contrast enhanced imaging(T1 and T2a).
Exclusion Criteria:
  • Patients who had other tumors

  • benign tumors

  • clinically unfit

  • metastatic RCC

  • patients with Clinical T2b or higher tumors,

  • tumors with maximum diameter > 10cm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sohag University Hospital Sohag Egypt

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ahmed Mahmoud Attia, assistent lecturer at urology department, Sohag University
ClinicalTrials.gov Identifier:
NCT05486871
Other Study ID Numbers:
  • Soh-Med-22-07-20
First Posted:
Aug 4, 2022
Last Update Posted:
Aug 4, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2022